Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models. Devarajan R, Izzi V, Peltoketo H, Rask G, et al. J Clin Invest 2025;135:e196478.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Devarajan R, Izzi V, Peltoketo H, Rask G, et al. Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models. J Clin Invest 2025;135:e196478.
PMID: 40759578